T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

(MedPage Today) — CHICAGO — Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115823

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

Immunotherapy drug doubles cancer survival in breakthrough trial

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

Pharmacists warn drug shortage affecting cancer patients

Tumor Treating Fields Boost Pancreatic Cancer Survival

Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer

In Pancreatic Cancer, Does New PAXG Beat Out mFOLFIRINOX?

Pharmacists warn drug shortage affecting cancer patients

Tumor Treating Fields Boost Pancreatic Cancer Survival

Alternative Endpoints in Phase III Trials Don’t Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer

In Pancreatic Cancer, Does New PAXG Beat Out mFOLFIRINOX?

‘This Is Not Just a Pandemic Story’: What We Heard This Week

Can New Biomarker Help Identify High-Risk DLBCL Patients?

Categories

Archives